These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6778528)

  • 41. The Gaucher mouse.
    Kanfer JN; Stephens MC; Singh H; Legler G
    Prog Clin Biol Res; 1982; 95():627-44. PubMed ID: 6812089
    [No Abstract]   [Full Text] [Related]  

  • 42. Uptake by neuroblastoma cells of glucosylceramide, glucosylceramide glucosidase, its stimulator protein, and phosphatidylserine.
    Datta SC; Snider RM; Radin NS
    Biochim Biophys Acta; 1986 Jul; 877(3):387-98. PubMed ID: 3730407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone marrow transplantation in Gaucher's disease: effect of mixed chimeric state.
    Chan KW; Wong LT; Applegarth D; Davidson AG
    Bone Marrow Transplant; 1994 Aug; 14(2):327-30. PubMed ID: 7994251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
    Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
    Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease.
    Beutler E; Beutler L; West C
    J Lab Clin Med; 2004 Aug; 144(2):65-8. PubMed ID: 15322500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity.
    Whitfield PD; Nelson P; Sharp PC; Bindloss CA; Dean C; Ravenscroft EM; Fong BA; Fietz MJ; Hopwood JJ; Meikle PJ
    Mol Genet Metab; 2002 Jan; 75(1):46-55. PubMed ID: 11825063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Preclinical research of a new therapy for Gaucher's disease with F213I mutation].
    Hou L; Kousaku O
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Oct; 20(5):381-4. PubMed ID: 14556188
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The possibility of increasing the precision of biochemical diagnostics of Gaucher disease].
    Horovenko NH; Drozdova VD; Nedoboĭ AM; Ol'khovych NV; Pichkur NO; Tsyhankova MA; Radzikhovs'ka OV
    Tsitol Genet; 2006; 40(3):67-71. PubMed ID: 16933855
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III.
    Nilsson O; Håkansson G; Dreborg S; Groth CG; Svennerholm L
    Clin Genet; 1982 Nov; 22(5):274-9. PubMed ID: 7151312
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current issues in enzyme therapy for Gaucher disease.
    Grabowski GA
    Drugs; 1996 Aug; 52(2):159-67. PubMed ID: 8841735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Gaucher's disease: pathogenesis, diagnosis and therapy].
    Pregun I; Tulassay Z
    Orv Hetil; 2004 Sep; 145(37):1883-90. PubMed ID: 15493618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunoquantification of beta-glucosidase: diagnosis and prediction of severity in Gaucher disease.
    Fuller M; Lovejoy M; Hopwood JJ; Meikle PJ
    Clin Chem; 2005 Nov; 51(11):2200-2. PubMed ID: 16179423
    [No Abstract]   [Full Text] [Related]  

  • 53. Hydrolysis of ceramide lactoside and ceramide glucoside by glycosidases from brain.
    Papavassiliou J
    Isr J Med Sci; 1965 Jul; 1(4):624-7. PubMed ID: 5842275
    [No Abstract]   [Full Text] [Related]  

  • 54. [The splenic cerebrosides in Guacher's disease].
    Valdiguié P; Douste-Blazy L; Dider A; Soula C
    Ann Biol Clin (Paris); 1965; 23(7):857-71. PubMed ID: 5843440
    [No Abstract]   [Full Text] [Related]  

  • 55. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans.
    Beutler E
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5384-90. PubMed ID: 8516282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repacement therapy in Gaucher disease.
    Beutler E; Dale GL; Kuhl W
    Birth Defects Orig Artic Ser; 1980; 16(1):369-81. PubMed ID: 6778528
    [No Abstract]   [Full Text] [Related]  

  • 57. Experiences after long-term treatment of a type I Gaucher disease patient with liposome-entrapped glucocerebroside: beta-glucosidase.
    Gregoriadis G; Neerunjun D; Meade TW; Goolamali SK; Weereratne H; Bull G
    Birth Defects Orig Artic Ser; 1980; 16(1):383-92. PubMed ID: 6778529
    [No Abstract]   [Full Text] [Related]  

  • 58. Liposomes in Gaucher type I disease: use in enzyme therapy and the creation of an animal model.
    Gregoriadis G; Weereratne H; Blair H; Bull GM
    Prog Clin Biol Res; 1982; 95():681-701. PubMed ID: 6812092
    [No Abstract]   [Full Text] [Related]  

  • 59. Status of enzyme replacement therapy for Gaucher disease.
    Brady RO; Barranger JA; Gal AE; Pentchev PG; Furbish FS
    Birth Defects Orig Artic Ser; 1980; 16(1):361-8. PubMed ID: 7004519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New directions in the treatment of Gaucher disease.
    Futerman AH; Sussman JL; Horowitz M; Silman I; Zimran A
    Trends Pharmacol Sci; 2004 Mar; 25(3):147-51. PubMed ID: 15019270
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.